Tissue Regenix Reports H1 Revenue Decline but Maintains Profitability Outlook

Tissue Regenix reports 6% H1 revenue decline to $13.8m but maintains positive adjusted EBITDA outlook and full-year profitability guidance.

8 September 2025by Joshua Thompson5 min read52 views

This article covers information on Tissue Regenix Group PLC.

LON:TRX

Tissue Regenix H1 2025 trading update: revenue slips, profit guidance intact

Tissue Regenix has reported a softer first half, with total Group revenue down 6% to $13.8m (H1 2024: $14.7m). The company points to weaker orders from strategic partners amid uncertain economic conditions, plus some regulatory approval delays hampering new market entries. Despite that, management expects a positive adjusted EBITDA for H1 2025 and remains confident of delivering adjusted EBITDA profitability for the full year, consistent with FY 2024.

New Executive Chairman, Jay LeCoque, has arrived with a clear focus on tightening operational and commercial execution. The near-term picture is mixed, but there are encouraging signs in the direct distribution channel that could set up a better second half if the momentum continues.

Headline numbers investors should know

Total Group revenue (H1 2025)	$13.8m
Year-on-year change	-6% (H1 2024: $14.7m)
BioRinse portfolio revenue	$9.8m (H1 2024: $10.5m)
dCELL portfolio revenue	Down 4% year-on-year (H1 2024: $4.2m)
Direct distribution revenue	Up 10% year-on-year
New distributors added	32 in H1 2025
Adjusted EBITDA (H1 2025)	Expected positive (figure not disclosed)
Cash position	Sufficient for organic growth plan (amount not disclosed)

What’s driving the dip? Partner softness and regulatory delays

The main headwind is softer ordering from strategic partners. A “strategic partner” is a large customer or collaborator that places recurring orders; when they slow down, it can materially affect revenue. Tissue Regenix also flags ongoing regulatory approval delays that are holding back new customer wins in new markets, which adds friction to growth in BioRinse and dCELL.

BioRinse fell to $9.8m from $10.5m, a meaningful step down that reflects both partner caution and the regulatory bottlenecks. This is the lion’s share of Group revenue, so weakness here matters. The balance of the first half now rests on whether partner ordering patterns normalise and whether approvals come through in time to influence H2.

dCELL and DermaPure: direct channel shows momentum

The dCELL portfolio (which includes DermaPure) decreased by 4% year-on-year overall, again due to lower orders from a strategic partner. However, the bright spot is the direct distribution network: revenue here grew by 10% year-on-year, underpinned by the addition of 32 new distributors in H1 2025. That suggests the company’s own commercial engine is gaining traction.

In practical terms, growing the direct channel reduces dependence on a few big partners and can improve pricing power over time. It does take effort and investment, and it won’t fully offset a sudden pause from a major partner overnight, but it is the right strategic direction in my view.

Share𝕏 in

Investing
Polar Capital Technology Trust Reports 102% NAV Growth in Stellar Fiscal Year
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Investing

Tagged

Last updated

5 July 2026

Star Rating

No ratings yet

Profitability outlook: adjusted EBITDA stays in the black

Adjusted EBITDA (earnings before interest, tax, depreciation and amortisation, adjusted for one-offs) is expected to be positive in H1 2025. Management also remains confident of achieving adjusted EBITDA profitability for the full year, “in line with” FY 2024. No profit figure is disclosed today, but holding profitability on a lower revenue base implies ongoing cost discipline.

The trade-off is clear: top-line growth is subdued, but costs appear under control. If partner orders stabilise and direct sales continue to grow, operating leverage could reassert in H2.

Cash position: enough for the plan, but details to come

The company states that cash at 30 June 2025 is sufficient to support its current organic growth plan and to drive growth in 2026. The absolute cash figure is not disclosed. That wording hints at a comfortable runway without near-term financing, which is supportive for sentiment, but the interim results should provide the detail on cash movements and working capital.

For now, the takeaway is that management does not see cash as a constraint on executing the plan.

New Executive Chairman: sharpening execution

Jay LeCoque joins as Executive Chairman and is prioritising tighter operational and commercial execution with a focus on sustainable, long-term earnings growth. Leadership changes at an inflection point can catalyse improvements in sales discipline, partner management and regulatory progress. The real test will be visible in H2 order trends and the cadence of new market entries once approvals are secured.

Key dates: interim results and investor presentation

Interim results publication: Thursday 18 September 2025.
Live online presentation (Investor Meet Company): 16:00 BST on Thursday 18 September. Registration: Investor Meet Company.
Company site: www.tissueregenix.com

Why it matters for Tissue Regenix shareholders

Positives to lean on

Adjusted EBITDA remains positive in H1 2025, with full-year profitability guidance maintained.
Direct distribution revenue grew 10% year-on-year, backed by 32 new distributors – a healthier sales mix over time.
Cash is stated as sufficient to fund the current plan into 2026, reducing near-term financing risk (amount not disclosed).

Risks to watch

Dependence on strategic partners: further ordering cuts would weigh on both BioRinse and dCELL.
Regulatory timing: delays are holding back new customers in new markets; any slippage into H2 would defer the revenue benefit.
Limited disclosure today: no gross margin, profit figures, or cash balance provided; clarity should arrive at the interims.

My take: cautious, with an eye on H2 catalysts

This update reads as a mid-year wobble rather than a strategic setback. The channel mix is moving in the right direction, and the company expects to keep the P&L in positive adjusted EBITDA territory despite revenue pressure. The two swing factors for the second half are partner order recovery and regulatory approvals unlocking new customers.

Into the 18 September interims, I’d focus on three items: the cash balance and burn, the split between partner and direct revenues, and any update on regulatory approval timelines. If the direct channel keeps compounding and partner demand normalises, Tissue Regenix could exit the year on a firmer footing.

Questions to ask management at the investor presentation

What proportion of Group revenue now comes from direct distribution versus strategic partners?
Which regulatory approvals are outstanding, and what are the expected timelines to clear them?
How is the order book looking into Q3 and Q4, particularly for BioRinse?
Any operational changes since Jay LeCoque’s appointment that will impact sales velocity or margins?
Capex and working capital outlook for H2 2025 and into 2026?

Bottom line: a short-term dip on the top line, but with profitability guidance intact and encouraging direct sales momentum. The interim results should fill in the blanks and determine whether this is a blip or the set-up for a cleaner second half.